-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

622. Lymphoma Biology—Non-Genetic Studies: Poster II

Lymphoma Biology—Non-Genetic Studies Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 10, 2017: 6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Robert Kridel1, Vindi Jurinovic2,3*, Pedro Farinha4,5*, Andreas Rosenwald6*, Ellen Leich7*, German Ott, MD8*, Heike Horn9,10*, Wolfram Klapper, MD11*, Michael Boesl2*, Wolfgang Hiddemann2*, Christian Steidl, MD12, Joseph M Connors, MD5, Laurie H. Sehn, MD, MPH5, Randy D. Gascoyne, MD5*, Eva Hoster2,3*, Oliver Weigert2* and Anja Mottok4,5,7*

1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Medical Department III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany
3Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig Maximilians University Munich, Munich, Germany
4Department of Pathology, BC Cancer Agency, Vancouver, BC, Canada
5Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada
6Institute of Pathology, University of Wuerzburg and Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany
7Institute of Pathology, University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany
8Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany
9Department of Clinical Pathology, Robert-Bosch-Hospital and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
10Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology Stuttgart, and University of Tuebingen, Stuttgart, Germany
11Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein Kiel, Kiel, Germany
12Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada

Shengjian Huang, PhD1*, Changying Jiang, PhD1*, Hui Guo, MD, PhD1*, Jeffrey Wang1*, Yang Liu, MD1*, Carrie Li2*, Elyse Lopez1*, Hui Zhang1*, Elizabeth A Lorence, MPH1*, Maria Merolle1*, Swathi Balaji1*, Makhdum Ahmed, MD, MPH, PhD1*, Krystle Nomie, PhD1*, Liang Zhang, MD, PhD1* and Michael Wang, MD1,3

1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston
3Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

Ravi Dashnamoorthy, PhD1, Benjamin Chen, MD, PhD2, Pallavi Galera3*, Hong Chang, PhD4*, Afshin Beheshti, PhD5, Srimoyee Ghosh, PhD6* and Andrew M. Evens, DO, MSc7

1Molecular Oncology Research Institute, Tufts Medical Center, Shrewsbury, MA
2UMass Memorial Medical Center, Worcester, MA
3University of Massachusetts Medical School, Worcester
4Institute for Clinical Research and Health Policy Studies and the Biostatistics, Epidemiology, and Research Design (BERD) Center, Tufts Medical Center, Boston, MA
5Molecular Oncology Research Institute, Boston, MA
6Tesaro, Waltham, MA
7Tufts University School of Medicine and Cancer Center, Boston, MA

Mohan Singh, PhD1, Parvesh Chaudhry, PhD1, Erik Gerdtsson, MS2*, Asaf Maoz, MD3*, Wendy Cozen, DO, MPH4, James Hicks, PhD5*, Peter Kuhn, PhD5*, Stephen Gruber, MD, PhD, MPH6*, Imran Siddiqi, MD, PhD7* and Akil Merchant, MD8

1Division of Hematology, Department of Medicine, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA
2Department of Biological Sciences,Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA
3Department of Oncology, University of Southern California, Los Angeles
4Norris Comprehensive Cancer Center, Department of Preventive Medicine and Pathology, Univ. of Southern California Norris Cancer Ctr., Los Angeles, CA
5Department of Biological Sciences, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA
6USC Norris Comprehensive Cancer Center, Los Angeles, CA
7Department of Pathology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA
8Department of Medicine-Hematology, USC Norris Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA

Weige Wang1,2,3*, Franzen Carrie4*, Madina Sukhanova5*, Venkataraman Girish1*, Ming Mei1*, Guo Ailin5*, Pin Lu, Ph.D.6*, Dong Sheng, MD7*, Gao Anhui8*, Xia Chunmei8*, Li Jia8*, Zhou Xiaoyan2* and Y Lynn Wang1

1Department of Pathology, University of Chicago, Chicago
2Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
3Department of Oncology, Fudan University Shanghai Medical School, Shanghai, China
4Department of Medicine, University of Chicago, Chicago
5University of Chicago, Chicago
6University of Chicago, Chicago, IL
7Shanghai Medical School, Shanghai, China
8State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Bethany L Mundy-Bosse, PhD1,2,3,4, Nathan Denlinger, MS, DO3, Susan Huang, MD3*, Li Chen3*, Hsiaoyin Mao3*, David Kline3*, Eric McLaughlin3*, Youssef Youssef5*, Karen Young3*, Gerard Lozanski, MD3, Aharon G. Freud, MD, PhD1,5,6, Pierluigi Porcu, MD7, Basem M. William, MD8*, Michael A. Caligiuri, MD1,4 and Anjali Mishra, PhD 1,9

1Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, Columbus, OH
2OSU Comprehensive Cancer Center, Columbus
3The Ohio State University, Columbus, OH
4Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
5Department of Pathology, The Ohio State University, Columbus, OH
6Comprehensive Cancer Center, The Ohio State University, Columbus, OH
7Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA
8Division of Hematology, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH
9Division of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, OH

Duncan Murray, FRCPath, MRCP, MA, BMBS1*, Suzy A Eldershaw, BSc. (Hons.), PhD.2*, Hayden Pearce, BSc. (Hons.), PhD.2*, Nathaniel Davies, MSci, PhD3*, Jack McMurray, BSc3*, Julia J. Scarisbrick, MD, FRCP, MBBS †4* and Paul Moss, MBBS, PhD, FRCP5

1Institute of Immunology, University of Birmingham, Birmingham, ENG, United Kingdom
2University of Birmingham, Birmingham, United Kingdom
3Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham, United Kingdom
4University Hospital Birmingham, Birmingham, United Kingdom
5Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

Pallavi Khattar, MD1*, Janine Pichardo, BS2*, Achim Jungbluth, MD PhD3*, Qi Gao4*, Eric L Smith, MD, PhD5, Mikhail Roshal, MD PhD4 and Ahmet Dogan, MD, PhD4,6

1Department of Hematopathology, Memorial Sloan Kettering Cancer Center, New York, NY
2Memorial SLoan Kettering Cancer Center, New York
3Memorial Sloan Kettering Cancer Center, New York
4Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
5Department of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center/New York Presbyterian, New York, NY
6Memorial Sloan Kettering Cancer Center, New York, NY

Joanne Soo, BS1,2, David M. Kurtz, MD1,3,4, Michael Jin1,5*, Florian Scherer, MD1*, Joseph G Schroers-Martin, MD1*, Mohammad S Esfahani, PhD1*, Alexander Craig, MPhil1*, Henning Stehr, PhD1*, Sattva S. Neelapu, MD6, Loretta Nastoupil, MD6, Mark Roschewski, MD7, Wyndham H. Wilson, MD, PhD8, Maximilian Diehn, MD, PhD9* and Ash A. Alizadeh, MD, PhD10,11,12

1Department of Medicine, Divisions of Hematology & Oncology, Stanford University Medical Center, Stanford, CA
2Duke University School of Medicine, Redwood City, CA
3Department of Bioengineering, Stanford University Medical Center, Stanford, CA
4Stanford University School of Medicine, Stanford, CA
5Stanford University, Stanford, CA
6Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
7Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
8National Cancer Institute, National Institutes of Health, Bethesda, MD
9Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA
10Institute for Stem Cell Biology and Regenerative Medicine, Stanford University Medical Center, Stanford, CA
11Department of Medicine, Divisions of Hematology & Oncology, Stanford University, Stanford, CA
12Stanford Cancer Institute, Stanford University Medical Center, Stanford, CA

Anke Maes1*, Eva De Smedt2*, Kim De Veirman3*, Ken Maes1*, Eline Menu, PhD1*, Els Van Valckenborgh, PhD4*, Karin Vanderkerken, PhD5 and Elke De Bruyne, PhD1*

1Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium
2Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, 1090 Jette, Belgium
3Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussel, Belgium
4Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussel, BEL
5Department of Hematology and Immunology, Myeloma Center Brussels, Free University of Brussels, Brussels, Belgium

Sudhakiranmayi Kuravi, M.S.1*, Elizabeth Parrott, M.A.1*, Siddhartha Ganguly, MD2*, Anusha Vallurupalli, MD1*, Yogenthiran Saunthararajah, MD3,4, Brian S Blagg, Ph.D.5*, Jensen Roy, MD1*, Joseph P. McGuirk, DO6 and Ramesh Balusu, PhD7

1University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS
2Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS
3Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Case Western Reserve Univ., Cleveland, OH
4Taussig Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
5University of Kansas, Lawrence, KS
6Department of Blood and Bone Marrow Transplant, The University of Kansas Medical Center, Kansas City, KS
7University of Kansas Medical Center, Kansas City, KS

Tanaya Shree, MD, PhD1, Sangeeta Kowli, PhD2*, Holden T. Maecker, PhD2* and Ronald Levy, MD1

1Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA
2Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Yasuhisa Sando, MD1*, Ken-ichi Matsuoka, MD, PhD1*, Yusuke Meguri, MD1*, Shuntaro Ikegawa, MD1*, Hiroyuki Sugiura, MD1*, Makoto Nakamura, MD2*, Iwamoto Miki1*, Takeru Asano, MD1*, Takanori Yoshioka, MD1* and Yoshinobu Maeda, MD, PhD1

1Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
2Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, OKA, Japan

Marjukka Pollari, MD1,2*, Oscar Brück3*, Suvi-Katri Leivonen, PhD1,4, Teijo Pellinen, PhD5*, Pauli Vähämurto1,6*, Marja-Liisa Karjalainen-Lindsberg7*, Susanna Mannisto, MD, PhD1,6*, Pirkko-Liisa Kellokumpu-Lehtinen, MD, prof2,8*, Satu Mustjoki, MD, PhD3,9 and Sirpa Leppa, MD1,4

1Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland
2Department of Oncology, Tampere University Hospital, Tampere, Finland
3Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland
4Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
5Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
6Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
7Department of Pathology, Helsinki University Hospital, Helsinki, Finland
8Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
9Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

Karin Tarte, PhD1,2*, Stephane Rodriguez, PhD3*, Patricia Ame-Thomas, PhD1,2*, Alexis Saintamand, PhD1*, Mehdi Alizadeh, PhD4*, Celine Monvoisin1*, Inaki Martin Subero, PhD5* and Thierry Lamy, Pr, MD, PhD1,2

1UMR U1236, Rennes, France
2CHU Rennes, Rennes, France
3Universite de Rennes, Rennes, France
4Etablissement Français du Sang Bretagne, Rennes, France
5Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

John Simon Van Arnam, MD, MS1*, Delphine C. M. Rolland, PharmD, PhD2, Kojo S.J. Elenitoba-Johnson, MD2, Megan S. Lim, MD, PhD1, Özlem Önder, PhD3*, Nathanael G. Bailey, MD4 and David Bahler, MD5

1Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
2University of Pennsylvania, Philadelphia, PA
3Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia
4UPMC, Pittsburgh, PA
5ARUP Laboratories, Salt Lake City, UT

Jennifer Crombie, MD1, Chen Lossos, BS2*, Kristopher Sarosiek, PhD2*, Amanda L Christie, BS1*, Cameron Fraser, BS2*, Shruti Bhatt, PhD1, Jing Deng, PhD1, Matthew S. Davids, MD1, David M. Weinstock, MD1 and Anthony Letai, MD, PhD1

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Harvard Medical School, Boston, MA

*signifies non-member of ASH